School of Life and Health Sciences Aston University Birmingham B4 7ETUK
Tel: +44 (0)121 204 4005 Email: firstname.lastname@example.org
I completed my PhD in Pharmacy in 2002 from Aston University having previously gained my
BSc (Hons) in Pharmacology (93) and MSc in Human and Animal Physiology (95) at Aberdeen University.
PGCert with Merit from Aston University (2014)
PGDip with merit From Aston University (2016)
NEBOSH general certificate with credit (2016)
These include cancer cachexia and metabolic changes in a number of conditions such as obesity and diabetes. I have mostly been examining an adipokine called zinc-alpha2-glycoprotein and its role in cachexia and obesity.
I teach on a number of programmes within Biology/Biomedical science and I am responsible for the running of the final year project laboratory.
I am the year 2 biology and BMS key skills module coordinator and teach the statistics portion of the course.
I am the module coordinator for BY3 PR1 BY3 PR2 and BY3 PR3 the Biology and BMS UG projects and BI4032 Masters projects.
I am also a personal and academic tutor.
I was awarded the Aston Excellence award for Community engagement for 2011. I have worked with a number of schools within the West Midlands running DNA master classes, ethical debates and microbiology. I have been a STEM ambassador for five years and I am on the Athena Swan working party for Life and Health Sciences
I am a Fellow of the Higher Education Academy
I am a member of the American Physiology Society and the Royal Society of Biology
Lattmann, E.; Russell, S.T.; Schwalbe, C.H.; Shortt, A.; Balaram, P.N.; Theochari, E.; Alharbi, M.; Narayanan, R.; Lattmann, P. Cholecystokinin-1 receptor antagonists : 5-hydroxy-5-aryl-pyrrol-2-ones as anticancer agents. (2016) MedChemComm, Vol. 7, No. 6, 01.06.2016, p. 1138-1145.
Russell ST, Tisdale MJ Role of b3-adrenergic receptors in the oral activity of zinc-a2 glycoprotein. Endocrinology (2012) 153: 4696-4704.
Russell ST, Tisdale MJ, Role of b3-adrenergic receptors in the anti-obesity and anti-diabetic effects of zinc-a2-glycoprotein (ZAG). Biochem et Biophys Acta 2012 1821:590-599
Russell ST, Tisdale MJ, Studies on the anti-obesity activity of zinc-α2-glycoprotein in the rat. Int J Obes (Lond). 2011 35(5):658-65.
Russell ST, Tisdale MJ, Studies on the antiobesity effect of zinc-α2-glycoprotein in the ob/ob mouse. Int J Obes (Lond). 2011 Mar;35(3):345-54
Russell ST, Tisdale MJ,Mechanism of attenuation of skeletal muscle atrophy by zinc-alpha2-glycoprotein. Endocrinology. 2010 Oct;151 (10):4696-704.
Russell ST, Siren PM, Siren MJ, Tisdale MJ. The role of zinc in the anti-tumour and anti-cachectic activity of D-myo-inositol 1,2,6-triphosphate. Br J Cancer. 2010 Mar 2;102 (5):833-6.
Eley HL, Russell ST, Tisdale MJ, Mechanism of activation of dsRNA-dependent protein kinase (PKR) in muscle atrophy. Cell Signal. 2010 May; 22(5):783-90.
Russell ST, Tisdale MJ,Antidiabetic properties of zinc-alpha2-glycoprotein in ob/ob mice. Endocrinology. 2010 Mar;151 (3):948-57
Russell ST, Siren PM, Siren MJ, Tisdale MJ, Mechanism of attenuation of protein loss in murine C2C12 myotubes by D-myo-inositol 1,2,6-triphosphate. Exp Cell Res. 2010 Jan 15;316(2):286-95.
Russell ST, Tisdale MJ, Mechanism of attenuation by beta-hydroxy-beta-methylbutyrate of muscle protein degradation induced by lipopolysaccharide. Mol Cell Biochem. 2009 Oct;330(1-2):171-9.
Russell ST, Siren PM, Siren MJ, Tisdale MJ, Attenuation of skeletal muscle atrophy in cancer cachexia by D-myo-inositol 1,2,6-triphosphate. Cancer Chemother Pharmacol. 2009 Aug;64(3):517-27
Russell ST, Rajani S, Dhadda RS, Tisdale MJ, Mechanism of induction of muscle protein loss by hyperglycaemia.Exp Cell Res. 2009 Jan 1;315(1):16-25.
Eley HL, Russell ST, Tisdale MJ, Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by beta-hydroxy-beta-methylbutyrate. Am J Physiol Endocrinol Metab. 2008 Dec;295(6):E1409-16.
Eley HL, Russell ST, Tisdale MJ. Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-alpha and angiotensin II by beta-hydroxy-beta-methylbutyrate.Am J Physiol Endocrinol Metab. 2008 Dec;295(6):E1417-26.
Eley HL, McDonald PS, Russell ST, Tisdale MJ,Inhibition of activation of dsRNA-dependent protein kinase and tumour growth inhibition.Cancer Chemother Pharmacol. 2009 Mar;63(4):651-9.
Eley HL, Russell ST, Tisdale MJ, Role of the dsRNA-dependent protein kinase (PKR) in the attenuation of protein loss from muscle by insulin and insulin-like growth factor-I (IGF-I). Mol Cell Biochem. 2008 Jun; 313(1-2):63-9.
Russell ST, Eley HL, Wyke SM, Tisdale MJ.Involvement of phosphoinositide 3-kinase and Akt in the induction of muscle protein degradation by proteolysis-inducing factor.Biochem J. 2008 Feb 1;409(3):751-9.
Eley HL, Russell ST, Tisdale MJ, Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J. 2007 Oct 1;407(1):113-20.
Eley HL, Russell ST, Baxter JH, Mukerji P, Tisdale MJ,Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli.Am J Physiol Endocrinol Metab. 2007 Oct;293(4):E923-31.
Russell ST, Adipokines have a role to play in the treatment of metabolic disease. Future Medicinal Chemistry. 2010 Dec 2(12): p17211724